U.S. Markets open in 7 hrs 18 mins

Apricus Biosciences, Inc. (APRI)

NASDAQ Capital Market - NASDAQ Capital Market Delayed Price. Currency in USD
Add to watchlist
1.48-0.01 (-0.67%)
At close: 4:00PM EDT
People also watch
BIOCETRMANTHPULMIDXG
  • S
    Shanawaz
    Shanawaz
    APRI - world wide - Great review from users and they are all recommending Vitaros best creme and easy to use. APRI NDA Resubmission data and approval looks very favorable 100%. Apri expecting will be at 3 bucks soon
  • M
    Maria
    Maria
    Downside risk pretty much eliminated now I would guess, thoughts? Yo you should really check out awesom_sto-cks, they seem on point with their stocks.
  • M
    Marinshell
    Marinshell
    A little perky in share price today!?!
  • M
    Moula
    Moula
    Why Vitaros is approved over 26 countries and still not approved in US ?
  • H
    Harry
    Harry
    I wonder how many people know Allergan has a right to buy rights to Vitaros for $25M upfront, milestone payments and royalties? If that happens the company will easily more than triple in value just based on that upfront payment alone.
  • D
    David Harrington
    David Harrington
    This is looking good today. See $2 soon.
  • D
    David Harrington
    David Harrington
    Looks like the corrupt crackpot legacy of Joey the Dogdoltski reigns with $RPRX latest failure! Pretty remarkable that investors put up with his obvious misleading of investors with his fake and faulty data. The problems continue for Repros. You just cannot undo years of mismanaged studies and negligence. Proellex will never get out of phase 2 ever. Too many safety problems ignored.
  • K
    Kaitlyn
    Kaitlyn
    Is APRI overvalued at current levels? have you guys heard of awe*some*stocks. i started receiving their allerts and so far i am happy.
  • M
    Marinshell
    Marinshell
    What do we learn as far as Corporate Developments today at 4:30 ET!?!
  • A
    Anonymous
    Anonymous
    Patent exipration on VIAGRA until 2020. Patent expiration of CIALIS Nov 2017. TEVA allowed to manufacture generic VIAGRA but have to pay royalty to PFIZER
  • D
    Dave
    Dave
    breakout $1.70++ news tommorow
  • M
    Marinshell
    Marinshell
    Interesting to note: Pfizer patent on Viagra is expiring this fall - open to generics and competition. Perhaps APRI may factor into Pfizer next steps for the ED market?
  • B
    BioNap
    BioNap

    KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float O/S 10.6 M / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension
    https://baystreet.ca/articles/research_reports/lifesci/Kitov062717.pdf

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets

    Products

    Kitov’s current pipeline products, KIT-301 and KIT-302, are combination drugs that treat OA pain and HTN simultaneously. In December 2015, KIT-302 successfully achieved the primary efficacy endpoint for its Phase III clinical trial. In August 2016, the United States Patent Office issued a patent covering KIT-302.

    Market

    Of the 27 million Americans with OA, 50% also suffer from HTN, which is also a common side effect of stand-alone OA drugs. With no single medication currently treating both conditions, KIT-301 and KIT-302 are targeting this multi-billion dollar market.

  • r
    richard
    richard

    Monster Microcaps Alert to APRI shareholders. Clean Energy Technologies (CETY) opened their Europe Sales and Service Center for Europe sales and to serve 65 existing customers with CETY’s General Electric clean energy heat recovery systems and has already sold the first of hundreds of units to come.

    Each CETY Heat Recovery System sells for $300,000 and market demand is reported to several BILLION DOLLARS.

    CETY purchased Heat Recovery Systems in 2015 from General Electric and products are now very attractive to huge unmet markets and can achieve over $250 million annual sales within the next 2 years. Demand for conversion of wasted heat to electrical energy in big applications is VERY LARGE AND UNMET.

    Shares are steal with target of $.20 by year end and higher in 12 months.

    https://finance.yahoo.com/news/clean-energy-technologies-inc-secures-144700111.html

    Clean Energy Technologies, Inc. Secures New Order for Waste Biomass Application in Europe
    COSTA MESA, Calif., July 12, 2017 /PRNewswire/ -- Clean Energy Technologies, Inc. (CETY) announced today that its subsidiary Heat Recovery Solutions has secured a new Clean CycleTM generator order for a Waste Biomass application in Europe. Growing d
    finance.yahoo.com
  • M
    Marinshell
    Marinshell
    What has these shares so firm (LOL)?
    Tremendous volume and it looks like it wants to run.
    I think the sale of the X-US rights may have been part of a much larger plan...
  • A
    Anonymous
    Anonymous
    OK, wow, this thing will be huge in US. ED affects millions. If this cream is approved in US as it has been in the other 26 countries, think about it...no more pills. throw this thing on and your good. OMG....Why is this so cheap, especially with the sale and closing they just did?
  • C
    Clarence
    Clarence
    well once again...Pascoe was wrong he said on the conference call he would hear frim the FDA in Q2...well that did not happen,,,
    anyone want me to list the 12 other mistakes Pascoe has made to date?
    some include a Canada Abbott Vitaros launch and launches that never happened....
    another a Femprox partner in Europe that never happned
    etc etc all lies? or is he just greatly mistaken to the point of being delusional?
  • H
    Harry
    Harry
    APRI's product, Vitaros, has already been approved in 26 countries including ones with sophisticated health agencies. That's why Ferring bought the non-US rights. With such widespread use and patient experience, it's very likely to be approved in the U.S., too, which would be the biggest market, of course. Argentina, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Lebanon, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Spain, Sweden, Switzerland and the United Kingdom.
  • N
    Neal
    Neal
    So the FDA approval of this new drug resubmission is anticipated for Q3, what's the potential of this new drug in dollars to APRI and its shareholders? Need some homework here, since they let go of there Ex operations to Farring, what are they making money on now?
  • J
    Joan
    Joan
    APRI may be a compelling opportunity. Im not sure about you guys but awe.some.stocks has provided me with some pretty good trade ideas. I messed up executing some of them but thats on me.